Andrea Tan
Stock Analyst at Goldman Sachs
(0)
# 4147
Out of 5,291 analysts
49
Total ratings
38.46%
Success rate
-8.68%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Day One Biopharmaceu... | Maintains: Buy | 39 27 | 8.07 | 234.57% | 6 | Mar 25, 2025 | |
Iovance Biotherapeut... | Maintains: Buy | 22 19 | 3.54 | 436.72% | 5 | Mar 3, 2025 | |
Tarsus Pharmaceutica... | Maintains: Neutral | 36 41 | 51.78 | -20.82% | 3 | Nov 15, 2024 | |
Insmed | Maintains: Strong Buy | 74 102 | 77.89 | 30.95% | 9 | Jul 10, 2024 | |
Sagimet Biosciences | Maintains: Neutral | 23 6 | 3.72 | 61.29% | 5 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 31 | 13.8 | 124.64% | 1 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Sell | 3 2 | 0.3 | 566.67% | 3 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Sell | 2 | 2.9 | -31.03% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 17 | n/a | n/a | 1 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 160 | 183.84 | -12.97% | 1 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 27 24 | 2.31 | 938.96% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Sell | 10 4 | 0.84 | 376.19% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 178 375 | 327.91 | 14.36% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Sell | 13 | 5.21 | 149.52% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 2 2 | n/a | n/a | 6 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 6 4 | 0.77 | 419.48% | 2 | May 24, 2022 |